These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36166463)

  • 1. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    Boyce CL; Beck IA; Styrchak SM; Hardy SR; Wallner JJ; Milne RS; Morrison RL; Shapiro DE; João EC; Mirochnick MH; Frenkel LM
    PLoS One; 2022; 17(9):e0275254. PubMed ID: 36166463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
    Frenkel LM; Morrison RL; Fuller TL; Gouvêa MI; Benamor Teixeira ML; Coombs RW; Shapiro DE; Mirochnick M; Hennessey R; Whitson K; Chakhtoura N; João EC
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):361-365. PubMed ID: 34369908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-frequency pre-treatment HIV drug resistance: effects on 2-year outcome of first-line efavirenz-based antiretroviral therapy.
    Milne RS; Beck IA; Levine M; So I; Andersen N; Deng W; Panpradist N; Kingoo J; Kiptinness C; Yatich N; Kiarie JN; Sakr SR; Chung MH; Frenkel LM
    AIDS; 2022 Nov; 36(14):1949-1958. PubMed ID: 36305180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
    Paredes R; Lalama CM; Ribaudo HJ; Schackman BR; Shikuma C; Giguel F; Meyer WA; Johnson VA; Fiscus SA; D'Aquila RT; Gulick RM; Kuritzkes DR;
    J Infect Dis; 2010 Mar; 201(5):662-71. PubMed ID: 20102271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Metzner KJ; Kozal MJ; Hullsiek KH; Balduin M; Jakobsen MR; Geretti AM; Thiebaut R; Ostergaard L; Masquelier B; Johnson JA; Miller MD; Kuritzkes DR
    JAMA; 2011 Apr; 305(13):1327-35. PubMed ID: 21467286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
    Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
    AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Geretti AM; Fox Z; Johnson JA; Booth C; Lipscomb J; Stuyver LJ; Tachedjian G; Baxter J; Touloumi G; Lehmann C; Owen A; Phillips A;
    PLoS One; 2013; 8(7):e69266. PubMed ID: 23874928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): results from a cohort study in Argentina.
    Rozenszajn M; Arazi-Caillaud S; Taicz M; Bologna R; Mangano A; Aulicino PC
    J Antimicrob Chemother; 2022 Jun; 77(7):1969-1973. PubMed ID: 35512329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
    McCluskey SM; Lee GQ; Kamelian K; Kembabazi A; Musinguzi N; Bwana MB; Muzoora C; Haberer JE; Hunt PW; Martin JN; Boum Y; Bangsberg DR; Harrigan PR; Siedner MJ
    AIDS Patient Care STDS; 2018 Jul; 32(7):257-264. PubMed ID: 29985647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.
    Cole SR; Edwards JK; Hall HI; Brookhart MA; Mathews WC; Moore RD; Crane HM; Kitahata MM; Mugavero MJ; Saag MS; Eron JJ;
    Clin Infect Dis; 2017 Jun; 64(11):1591-1596. PubMed ID: 28498892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretreatment low-abundance HIV-1 drug resistance on virological failure after 1 year of antiretroviral therapy in China.
    Li M; Song C; Hu J; Dong A; Kang R; Feng Y; Xing H; Ruan Y; Shao Y; Hong K; Liao L
    J Antimicrob Chemother; 2023 Nov; 78(11):2743-2751. PubMed ID: 37769159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.
    Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D
    Clin Infect Dis; 2019 Jul; 69(2):207-214. PubMed ID: 30321314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food insecurity, drug resistance and non-disclosure are associated with virologic non-suppression among HIV pregnant women on antiretroviral treatment.
    Chohan BH; Ronen K; Khasimwa B; Matemo D; Osborn L; Unger JA; Drake AL; Beck IA; Frenkel LM; Kinuthia J; John-Stewart G
    PLoS One; 2021; 16(8):e0256249. PubMed ID: 34407133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.